✦ LIBER ✦
A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability
✍ Scribed by ten Cate, B; Bremer, E; de Bruyn, M; Bijma, T; Samplonius, D; Schwemmlein, M; Huls, G; Fey, G; Helfrich, W
- Book ID
- 109887065
- Publisher
- Nature Publishing Group
- Year
- 2009
- Tongue
- English
- Weight
- 260 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0887-6924
No coin nor oath required. For personal study only.